Patents by Inventor Roderich Suessmuth

Roderich Suessmuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210017229
    Abstract: It is provided a chemical compound according to general formula (1)
    Type: Application
    Filed: March 28, 2019
    Publication date: January 21, 2021
    Applicant: TECHNISCHE UNIVERSITÄT BERLIN
    Inventors: Roderich SUESSMUTH, Stefan GRAETZ, Iraj BEHROZ, Leonard VON ECKARDSTEIN, Patrick Michael DURKIN, John WESTON, Lieby ZBOROVSKY
  • Publication number: 20210009507
    Abstract: The invention relates to a method for the preparation of a 4,5-dihydroxyisoleucine derivative comprising the steps of asymmetric Claisen rearrangement of a Z-aminocrotyl-glycin ester and subsequent kinetic resolution of the product diastereomer mix by acylase, and subsequent Sharpless dihydroxylation of the resulting 2-amino-3-methylpent-4-enoic acid derivative.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 14, 2021
    Applicants: Heidelberg Pharma Research GmbH, Corden Pharma International GmbH
    Inventors: Caroline Knittel, Mary-Ann Siegert, Roderich Süssmuth, Christoph Wink, Gerhard Jas
  • Patent number: 10738316
    Abstract: A method for obtaining at least one microbial secondary metabolite or a derivative thereof, the method includes the step of heterologous expression of at least one synthetase of the secondary metabolite in at least one filamentous fungus. Also disclosed is an expression cassette, a plasmid vector including the expression cassette, an expression host, cyclodepsipeptides and a chimeric cyclodepsipeptide synthetase.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: August 11, 2020
    Assignee: TECHNISCHE UNIVERSITÄT BERLIN
    Inventors: Simon Boecker, Dirk Storm, Vera Meyer, Lennart Richter, Sophia Zobel, Franziska Wanka, Roderich Suessmuth, Agnes Muehlenweg
  • Publication number: 20200199640
    Abstract: The proposed solution refers to a host cell for the heterologous synthesis of at least one omphalotin compound comprising polynucleotides encoding for polypeptides involved in the omphalotin biosynthesis, an expression vector comprising said polynucleotides and a process for obtaining at least one omphalotin compound from said host cell.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: TECHNISCHE UNIVERSITÄT BERLIN
    Inventors: Sascha RAMM, Agnes MUEHLENWEG, Annette POCH-HASNEK, Eva MOESKER, Roderich SUESSMUTH, Bartlomiej KRAWCZYK
  • Publication number: 20200165214
    Abstract: A chemical compound is provided according to general formula (1):
    Type: Application
    Filed: December 21, 2017
    Publication date: May 28, 2020
    Applicant: TECHNISCHE UNIVERSITÄT BERLIN
    Inventors: Roderich SUESSMUTH, Dennis KERWAT, Stefan GRAETZ, Iraj BEHROZ, Leonard VON ECKARDSTEIN, Patrick Michael DURKIN, Marius MORKUNAS, John WESTON
  • Patent number: 10308595
    Abstract: Antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which include carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections are also disclosed.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: June 4, 2019
    Assignee: TECHNISCHE UNIVERSITÄT BERLIN
    Inventors: Roderich Suessmuth, Julian Kretz, Vivien Schubert, Alexander Pesic, Manuela Huegelland, Monique Royer, Stephane Cociancich, Philippe Rott, Dennis Kerwat, Stefan Graetz
  • Patent number: 10065133
    Abstract: The present invention provides phosphoryl choline derivatives of general formula (I), which are suitable to be immobilized on a solid support to provide a separation material of general formula (II), which bind with both high affinity and high specificity to a protein, more specifically to C-reactive protein and anti-phosphoryl choline antibodies. Said separation materials are particularly useful in the extracorporeal removal of C-reactive protein and anti-phosphoryl choline antibodies from a biological fluid of a patient for prophylaxis and/or treatment of immune dysfunctions and cardiovascular diseases. Also provided is a column that comprises the separation material of general formula (II), as well as a device containing the column. Formula (I), wherein variable X is selected from: —SH, —NHR3, —C?CH, —CH?CH2, —N3 and —CHO; the other variables are as defined in the claims: Formula (II), wherein variable “A” represents a solid support. “A” as well as the other variables are defined in detail in the claims.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 4, 2018
    Assignee: Pentracor GmbH
    Inventors: Victor Prisyazhnoy, Stephan Mattecka, Ahmed Sheriff, Roderich Süssmuth
  • Publication number: 20170137832
    Abstract: A method for obtaining at least one microbial secondary metabolite or a derivative thereof, the method includes the step of heterologous expression of at least one synthetase of the secondary metabolite in at least one filamentous fungus. Also disclosed is an expression cassette, a plasmid vector including the expression cassette, an expression host, novel cyclodepsipeptides and a chimeric cyclodepsipeptide synthetase.
    Type: Application
    Filed: March 20, 2015
    Publication date: May 18, 2017
    Applicant: TECHNISCHE UNIVERSITAET BERLIN
    Inventors: Simon BOECKER, Dirk STORM, Vera MEYER, Lennart RICHTER, Sophia ZOBEL, Franziska WANKA, Roderich SUESSMUTH, Agnes MUEHLENWEG
  • Publication number: 20170120163
    Abstract: The present invention provides phosphoryl choline derivatives of general formula (I), which are suitable to be immobilized on a solid support to provide a separation material of general formula (II), which bind with both high affinity and high specificity to a protein, more specifically to C-reactive protein and anti-phosphoryl choline antibodies. Said separation materials are particularly useful in the extracorporeal removal of C-reactive protein and anti-phosphoryl choline antibodies from a biological fluid of a patient for prophylaxis and/or treatment of immune dysfunctions and cardiovascular diseases. Also provided is a column that comprises the separation material of general formula (II), as well as a device containing the column. Formula (I), wherein variable X is selected from: —SH, —NHR3, —C?CH, —CH?CH2, —N3and —CHO; the other variables are as defined in the claims: Formula (II), wherein variable “A” represents a solid support. “A” as well as the other variables are defined in detail in the claims.
    Type: Application
    Filed: June 19, 2015
    Publication date: May 4, 2017
    Inventors: Victor Prisyazhnoy, Stephan Mattecka, Ahmed Sheriff, Roderich Süssmuth
  • Publication number: 20150376120
    Abstract: Antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which include carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections are also disclosed.
    Type: Application
    Filed: February 14, 2014
    Publication date: December 31, 2015
    Inventors: Roderich SÜSSMUTH, Julian KRETZ, Vivien SCHUBERT, Alexander PESIC, Manuela HÜGELLAND, Monique ROYER, Stéphane COCIANCICH, Philippe ROTT, Dennis KERWAT, Stefan GRÄTZ
  • Publication number: 20150274787
    Abstract: The present invention relates to a method for recombinant production of Labyrinthopeptins and functional derivatives thereof. Moreover, the present invention relates to novel functional derivatives of Labyrinthopeptins.
    Type: Application
    Filed: December 19, 2012
    Publication date: October 1, 2015
    Inventors: Joachim Wink, Mark Broenstrup, Stefan Bartoschek, Luigi Toti, Roderich Suessmuth, Joanna Krawczyk
  • Patent number: 8476222
    Abstract: The disclosure relates to a compound of the formula (I) wherein R1 is H, C(O)—(C1-C6)alkyl or C(O)—O—(C1-C6)alkyl; R2 is OH, NH2, NH—(C1-C6)alkyl, NH—(C1-C4)alkylene-phenyl or NH—(C1-C4)alkylene-pyridyl; R3 and R4 are independently of each other H or OH, or R3 and R4 together are ?O; and m and n are independently of one another 0, 1 or 2; in any stereochemical form, or a mixture of any stereochemical forms in any ratio, or a physiologically acceptable salt thereof, obtainable from Actinomadura namibiensis (DSM 6313), and its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: July 2, 2013
    Assignee: Sanofi
    Inventors: Gerhard Seibert, László Vértesy, Joachim Wink, Irvin Winkler, Mark Broenstrup, Holger Hoffmann, Hans Guehring, Luigi Toti, Roderich Süssmuth, George M. Sheldrick, Kathrin Meindl
  • Publication number: 20110144001
    Abstract: The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) wherein {A}, {B}, {C}, R1-R6, m and n are as defined herein, obtainable from microorganism strain Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, a pharmaceutical composition comprising it, prepro-Labyrinthopeptin, pro-Labyrinthopeptin, and DNA coding for prepro-Labyrinthopeptin and pro-Labyrinthopeptin.
    Type: Application
    Filed: September 30, 2010
    Publication date: June 16, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Mark BROENSTRUP, Hans GUEHRING, Holger HOFFMANN, Joachim WINK, Roderich SUESSMUTH, Timo SCHMIEDERER
  • Publication number: 20090298904
    Abstract: The disclosure relates to a compound of the formula (I) wherein m and n are independently of one another 0, 1 or 2, obtainable from Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.
    Type: Application
    Filed: April 2, 2009
    Publication date: December 3, 2009
    Applicant: sanofi-aventis
    Inventors: Gerhard Seibert, László Vértesy, Joachim Wink, Irvin Winkler, Mark Broenstrup, Holger Hoffmann, Hans Guehring, Luigi Toti, Roderich Süssmuth, George M. Sheldrick, Kathrin Meindl
  • Patent number: 6794170
    Abstract: The invention relates to a process halogenation, which comprises halogenating a chemical compound in the presence of a halogenase, where the halogenase is (a) encoded by the sequence specified in SEQ ID NO: 1 or a sequence derived therefrom on the basis of the degeneracy of the genetic code, or is (b) encoded by a nucleic acid sequence which codes for a functional fragment of (a) or (c) by a sequence which hybridizes with (a) or (b) under standard conditions, or is (d) encoded by a sequence which has more than 30% identity or more than 60% similarity with the sequence specified under (a).
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 21, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Stefan Pelzer, Petra Huber, Roderich Suessmuth, Juergen Recktenwald, Dorothée Heckmann, Wolfgang Wohlleben
  • Patent number: 6660835
    Abstract: The present invention relates to peptides, which are useful in treating Staphylococcus infections. More particularly, the inventive peptides interfere with the regulation of the agr system of Staphylococcus species, especially S. aureus, and thereby block the formation of different virulence factors. The inventive peptides comprise at least the amino acid sequence S V X A S Y F, whereby cyclic structures of that kind of peptides are the most potent blocking reagents.
    Type: Grant
    Filed: December 24, 1998
    Date of Patent: December 9, 2003
    Inventors: Michael Otto, Roderich Suessmuth, Guenther Jung, Friedrich Goetz
  • Publication number: 20030096335
    Abstract: The invention relates to a process halogenation, which comprises halogenating a chemical compound in the presence of a halogenase, where the halogenase is
    Type: Application
    Filed: April 5, 2002
    Publication date: May 22, 2003
    Inventors: Stefan Pelzer, Petra Huber, Roderich Suessmuth, Juergen Recktenwald, Dorothee Heckmann, Wolfgang Wohlleben
  • Patent number: 6566110
    Abstract: The invention relates to a process halogenation, which comprises halogenating a chemical compound in the presence of a halogenase, where the halogenase is (a) encoded by the sequence specified in SEQ ID NO: 1 or a sequence derived therefrom on the basis of the degeneracy of the genetic code, or is (b) encoded by a nucleic acid sequence which codes for a functional fragment of (a) or (c) by a sequence which hybridizes with (a) or (b) under standard conditions, or is (d) encoded by a sequence which has more than 30% identity or more than 60% similarity with the sequence specified under (a).
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: May 20, 2003
    Assignee: BASF Aktiengesellschaft
    Inventors: Stefan Pelzer, Petra Huber, Roderich Suessmuth, Juergen Recktenwald, Dorothee Heckmann, Wolfgang Wohlleben